Geographic Atrophy (GA) - Pipeline Insight, 2020
![](/report_cover/8047/geographic-atrophy-ga-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 48-72 Hours
Geographic Atrophy (GA)
Overview
'Geographic Atrophy (GA)
Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Geographic Atrophy (GA)
Market. A Detailed Picture Of The Geographic Atrophy (GA)
Pipeline Landscape Is Provided, Which Includes The Disease Overview And Geographic Atrophy (GA)
Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth Geographic Atrophy (GA)
Commercial Assessment And Clinical Assessment Of The Geographic Atrophy (GA)
Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Geographic Atrophy (GA)
Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Geographic Atrophy (GA)
Of Pipeline Development Activities
The Report Provides Insights Into:
Analytical Perspective By DelveInsight
This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.
The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.
SCOPE OF THE REPORT
Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
REPORT HIGHLIGHTS
Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Geographic Atrophy (GA)
Market Size In The Coming Years.
KEY QUESTIONS
?
Geographic Atrophy (GA)
Overview
'Geographic Atrophy (GA)
Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Geographic Atrophy (GA)
Market. A Detailed Picture Of The Geographic Atrophy (GA)
Pipeline Landscape Is Provided, Which Includes The Disease Overview And Geographic Atrophy (GA)
Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth Geographic Atrophy (GA)
Commercial Assessment And Clinical Assessment Of The Geographic Atrophy (GA)
Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Geographic Atrophy (GA)
Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Geographic Atrophy (GA)
Of Pipeline Development Activities
The Report Provides Insights Into:
- All Of The Companies That Are Developing Therapies For The Treatment Of Geographic Atrophy (GA)
- Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Geographic Atrophy (GA)
- Geographic Atrophy (GA)
- Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
- Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Geographic Atrophy (GA)
- The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.
Analytical Perspective By DelveInsight
- In-Depth Geographic Atrophy (GA)
This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.
- Geographic Atrophy (GA)
The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.
SCOPE OF THE REPORT
- The Geographic Atrophy (GA)
Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
- It Comprises Of Detailed Profiles Of Geographic Atrophy (GA)
- Detailed Geographic Atrophy (GA)
- Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Geographic Atrophy (GA)
REPORT HIGHLIGHTS
- A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Geographic Atrophy (GA)
- In The Coming Years, The Geographic Atrophy (GA)
- The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Geographic Atrophy (GA)
- A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Geographic Atrophy (GA)
Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Geographic Atrophy (GA)
Market Size In The Coming Years.
- Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Geographic Atrophy (GA)
KEY QUESTIONS
- What Are The Current Options For Geographic Atrophy (GA)
- How Many Companies Are Developing Therapies For The Treatment Of Geographic Atrophy (GA)
- What Are The Principal Therapies Developed By These Companies In The Industry?
- How Many Therapies Are Developed By Each Company For The Treatment Of Geographic Atrophy (GA)
- How Many Geographic Atrophy (GA)
?
- Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
- What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Geographic Atrophy (GA)
- Which Are The Dormant And Discontinued Products And The Reasons For The Same?
- What Is The Unmet Need For Current Therapies For The Treatment Of Geographic Atrophy (GA)
- What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Geographic Atrophy (GA)
- What Are The Clinical Studies Going On For Geographic Atrophy (GA)
- What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
- What Are The Key Designations That Have Been Granted For The Emerging Therapies For Geographic Atrophy (GA)
- How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Geographic Atrophy (GA)
1. REPORT INTRODUCTION
2. GEOGRAPHIC ATROPHY (GA)
2.1. Overview
2.2. History
2.3. Geographic Atrophy (GA)
Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Geographic Atrophy (GA)
Diagnosis
2.6.1. Diagnostic Guidelines
3. GEOGRAPHIC ATROPHY (GA)
Current Treatment Patterns
3.1. Geographic Atrophy (GA)
Treatment Guidelines
4. GEOGRAPHIC ATROPHY (GA)
- DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Geographic Atrophy (GA)
companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Geographic Atrophy (GA)
Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Geographic Atrophy (GA)
Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. GEOGRAPHIC ATROPHY (GA)
Late Stage Products (Phase-III)
7. GEOGRAPHIC ATROPHY (GA)
Mid Stage Products (Phase-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. GEOGRAPHIC ATROPHY (GA)
Discontinued Products
13. GEOGRAPHIC ATROPHY (GA)
Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. GEOGRAPHIC ATROPHY (GA)
Key Companies
15. GEOGRAPHIC ATROPHY (GA)
Key Products
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. GEOGRAPHIC ATROPHY (GA)
Unmet Needs
18. GEOGRAPHIC ATROPHY (GA)
Future Perspectives
19. GEOGRAPHIC ATROPHY (GA)
Analyst Review
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
2. GEOGRAPHIC ATROPHY (GA)
2.1. Overview
2.2. History
2.3. Geographic Atrophy (GA)
Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Geographic Atrophy (GA)
Diagnosis
2.6.1. Diagnostic Guidelines
3. GEOGRAPHIC ATROPHY (GA)
Current Treatment Patterns
3.1. Geographic Atrophy (GA)
Treatment Guidelines
4. GEOGRAPHIC ATROPHY (GA)
- DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Geographic Atrophy (GA)
companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Geographic Atrophy (GA)
Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Geographic Atrophy (GA)
Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. GEOGRAPHIC ATROPHY (GA)
Late Stage Products (Phase-III)
7. GEOGRAPHIC ATROPHY (GA)
Mid Stage Products (Phase-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. GEOGRAPHIC ATROPHY (GA)
Discontinued Products
13. GEOGRAPHIC ATROPHY (GA)
Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. GEOGRAPHIC ATROPHY (GA)
Key Companies
15. GEOGRAPHIC ATROPHY (GA)
Key Products
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. GEOGRAPHIC ATROPHY (GA)
Unmet Needs
18. GEOGRAPHIC ATROPHY (GA)
Future Perspectives
19. GEOGRAPHIC ATROPHY (GA)
Analyst Review
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
LIST OF TABLES
Table 1: Geographic Atrophy (GA)
Diagnostic Guidelines
Table 2: Geographic Atrophy (GA)
Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Geographic Atrophy (GA)
Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Geographic Atrophy (GA)
Late Stage Products (Phase-III)
Table 18: Geographic Atrophy (GA)
Mid Stage Products (Phase-II)
Table 19: Geographic Atrophy (GA)
Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
Table 1: Geographic Atrophy (GA)
Diagnostic Guidelines
Table 2: Geographic Atrophy (GA)
Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Geographic Atrophy (GA)
Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Geographic Atrophy (GA)
Late Stage Products (Phase-III)
Table 18: Geographic Atrophy (GA)
Mid Stage Products (Phase-II)
Table 19: Geographic Atrophy (GA)
Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
LIST OF FIGURES
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Geographic Atrophy (GA)
companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Geographic Atrophy (GA)
Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Geographic Atrophy (GA)
companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Geographic Atrophy (GA)
Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs